Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: ER-positive Breast Cancer|HER2-negative Breast Cancer|Metastatic Cancer
Interventions: DRUG: Onapristone|DRUG: Fulvestrant
Sponsor: University of Wisconsin, Madison
Collaborators: Context Therapeutics Inc.